Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine

Merck & Co., Inc. (NYSE: MRK) revealed Monday about two regulatory milestones for its investigational vaccine for Ebola Zaire, ...